Precisio Biotix Therapeutics Inc. has entered into an agreement with Mayo Clinic that will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections. Precisio creates lower cost novel precision biological antibacterials with a focus on lung and skin infections.
Ono Pharmaceutical Co. Ltd. has entered into a collaboration agreement with Sibylla Biotech SpA to generate novel drug candidates for neurological disorders. Under this collaboration, Sibylla will utilize its proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) protein degradation technology platform.
Boehringer Ingelheim Pharma GmbH & Co KG and Sosei Group Corp. have entered a global collaboration and exclusive option-to-license agreement in schizophrenia.
The Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP) has awarded funding to Biosplice Therapeutics Inc.’s collaboration with The Roskamp Institute aimed at developing novel therapies for traumatic brain injury (TBI).
Fibrocor Therapeutics Inc. has entered into a research and development collaboration with the Mcquade Center for Strategic Research and Development LLC (MSRD).
C4 Therapeutics Inc. has entered into a license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins.
Dyadic International Inc.'s Dutch subsidiary, Dyadic Nederland BV, has entered into a strategic partnership agreement and collaboration with Rabian BV to develop efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
Max Biopharma Inc. and Metaba LLC are collaborating to study the effects of oxysterol drug candidates that target metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH), idiopathic pulmonary fibrosis, chronic inflammation, and atherosclerosis on metabolic processes.
Neomorph Inc. has entered into a collaboration and licensing agreement with Novo Nordisk A/S to discover, develop and commercialize molecular glue degraders.
Abbvie Inc. and Tentarix Biotherapeutics Inc. have established a multiyear collaboration focused on the discovery and development of conditionally active, multispecific biologic candidates against one target in oncology and another in immunology.
RSS
